Heron Therapeutics Inc (HRTX) Given Consensus Recommendation of “Buy” by Analysts

Shares of Heron Therapeutics Inc (NASDAQ:HRTX) have earned a consensus rating of “Buy” from the thirteen ratings firms that are currently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and eleven have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $29.56.

Several research firms recently issued reports on HRTX. BidaskClub upgraded Heron Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, December 20th. Oppenheimer set a $27.00 price target on Heron Therapeutics and gave the stock a “buy” rating in a research report on Thursday, December 14th. Mizuho restated a “buy” rating and set a $28.00 price target on shares of Heron Therapeutics in a research report on Friday, December 8th. Cowen reiterated a “buy” rating and issued a $40.00 price objective on shares of Heron Therapeutics in a research report on Wednesday, December 6th. Finally, ValuEngine upgraded Heron Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, November 30th.

Shares of Heron Therapeutics (NASDAQ:HRTX) traded up $0.70 during midday trading on Monday, hitting $18.35. The company had a trading volume of 1,599,300 shares, compared to its average volume of 854,587. The stock has a market cap of $1,132.76, a PE ratio of -4.84 and a beta of 2.13. The company has a current ratio of 2.12, a quick ratio of 2.02 and a debt-to-equity ratio of 0.62. Heron Therapeutics has a 52 week low of $12.21 and a 52 week high of $18.65.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.77) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.87) by $0.10. Heron Therapeutics had a negative return on equity of 385.11% and a negative net margin of 831.89%. The company had revenue of $8.57 million for the quarter, compared to analysts’ expectations of $8.12 million. sell-side analysts anticipate that Heron Therapeutics will post -3.41 earnings per share for the current fiscal year.

A number of large investors have recently made changes to their positions in HRTX. Legal & General Group Plc raised its stake in shares of Heron Therapeutics by 26.6% in the second quarter. Legal & General Group Plc now owns 11,354 shares of the biotechnology company’s stock worth $157,000 after purchasing an additional 2,383 shares during the last quarter. Quantbot Technologies LP increased its position in Heron Therapeutics by 2,619.6% during the second quarter. Quantbot Technologies LP now owns 12,483 shares of the biotechnology company’s stock valued at $172,000 after acquiring an additional 12,024 shares during the last quarter. Trexquant Investment LP purchased a new stake in Heron Therapeutics during the third quarter valued at $206,000. Jane Street Group LLC purchased a new stake in Heron Therapeutics during the third quarter valued at $223,000. Finally, HighTower Advisors LLC increased its position in Heron Therapeutics by 11.4% during the second quarter. HighTower Advisors LLC now owns 16,584 shares of the biotechnology company’s stock valued at $231,000 after acquiring an additional 1,700 shares during the last quarter. Institutional investors and hedge funds own 98.78% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Heron Therapeutics Inc (HRTX) Given Consensus Recommendation of “Buy” by Analysts” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another website, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The correct version of this piece can be accessed at https://www.com-unik.info/2017/12/25/heron-therapeutics-inc-hrtx-given-consensus-recommendation-of-buy-by-analysts.html.

About Heron Therapeutics

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit